Surprised it's so small given the potentially novel schizophrenia drug (BL-1020) in Phase 2/3. I would think that alone might merit a much higher market cap given potential and results to date. They also have several other drugs in their pipeline (http://www.biolinerx.com/default.asp?pageid=18 ) but I don't know much about them and whether it's just a case of quantity without any quality.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.